Clinical trials

Since POETIC's inception, two first-in-child clinical trials have been conducted increasing early access to novel molecularly targeted agents for treatment of children and adolescents with refractory malignancies after completion of adult Phase I studies. One of the studies resulted in evidence of clinical benefit in patients with tumors of the central nervous system using a novel agent targeting the epidermal growth factor receptor, cetuximab. These findings have provided the scientific rationale for a Phase II study targeting high grade central nervous system tumors, which is on-going.

Active clinical trials

Closed to accrual

Completed studies

  • Phase I trial of Cabazitaxel in patients with solid tumors including CNS
  • Phase I trial of Cabazitaxel in patients with solid tumors including CNS
  • Phase I trial of 17-AAG in patients with solid tumors and leukemia
  • Phase I trial of Cetuximab and Irinotecan in patients with solid tumors including CNS
  • Phase I trial of Oxaliplatin, Fluorouracil, and Leucovorin  in patients with solid tumors
  • Phase I trial of Clofarabine and Cyclophosphamide  in patients with leukemia
  • Phase I trial of Ridaforolimus  in patients with solid tumors
  • Safety and pharmacokinetics of Atezolisumb (MPDL3280A) in pediatric and young adults patients with previously treated solid tumors

Return to Top

 Pediatric Oncology Experimental Therapeutics Investigators' Consortium

© Copyright 2021  |   Website designed by Amanda M. Buckley

Connect

toll-free
(650) 736-0269

email
poeticdcc@stanford.edu